4D Molecular rises on positive interim data for eye injection

4D Molecular Therapeutics

14/11/2022 14:25

** Shares of 4D Molecular Therapeutics  FDMT.O  up ~20% at
$14.98 premarket
    ** Co reports interim data from ongoing early- to mid-stage
study of 4D-150, its investigational eye injection shot for
treating wet age-related macular degeneration  urn:newsml:reuters.com:*:nGNXfLB8n
    ** Wet macular degeneration is an eye disorder that causes
blurred vision or blind spots in the visual field, generally
caused by abnormal blood vessels leaking blood into the retina 
    ** Treatment reduced the frequency of anti-VEGF injection
needed by the patients by 96.7% - FDMT
    ** Anti-VEGF (anti–vascular endothelial growth factor) drugs
are a group of medicines that reduce new blood vessel growth and
are used for treating eye conditions related to it
    ** FDMT says its treatment was found to be safe and
tolerable, with no clinically significant eye inflammation
observed in study
    ** Up to Friday's close, stock down ~43% YTD
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))